Aarti Drugs Ltd

Aarti Drugs Management Change

Aarti Drugs Ltd announced the retirement of Director Uday M. Patil and the appointment of new directors, including Adhish P. Patil as the Managing Director.

Aarti Drugs Investor Presentation: Key Takeaways

Aarti Drugs reports Q1 FY27 revenue of ₹704 Cr, up 19% YoY. Management focuses on scaling regulated market sales through high-margin formulations and oncology backward integration.

Aarti Drugs Annual General Meeting

Aarti Drugs Limited conducted its 41st Annual General Meeting on September 26, 2026, to consider various ordinary and special business resolutions.

Aarti Drugs Annual General Meeting

Aarti Drugs Ltd has issued a notice for its 41st Annual General Meeting scheduled for September 26, 2026. The agenda includes financial statements and director appointments.

Aarti Drugs Annual Report

Aarti Drugs has released its Annual Report for FY 2025-26 and notice for its 41st Annual General Meeting scheduled for September 26, 2026.

Aarti Drugs Investor Presentation: Key Takeaways

Aarti Drugs reported Q1 FY27 revenue of ₹703.6 Cr, up 19% YoY, with EBITDA rising 30% to ₹96.9 Cr. Strategy focuses on backward integration at Sayakha and USFDA-regulated market expansion.

Aarti Drugs Investor Presentation: Key Takeaways

Aarti Drugs reported Q1FY27 revenue of ₹703.6 Cr with 19% YoY growth. EBITDA rose 30% to ₹96.9 Cr, driven by volume growth and improved pricing realizations across API and Specialty Chemicals portfolios.

Aarti Drugs Q1 FY27 Results: Net Profit ₹50.1 Cr, Down 7.2% YoY

Aarti Drugs Ltd reported revenue from operations of ₹702.8 Cr (+19.0% YoY) and net profit of ₹50.1 Cr (-7.2% YoY) for Q1 FY27.

Key figure

Net profit ₹50.1 Cr · -7.2% YoY

Aarti Drugs Earnings Call: Key Takeaways

Aarti Drugs reported Q4 FY26 revenue of ₹721.1 Cr (up 6% YoY) with EBITDA margins at 13.4%. Management is transitioning from investment to an operational scale-up phase despite geopolitical headwinds.

Aarti Drugs Earnings Call: Key Takeaways

Aarti Drugs reported FY26 revenue of ₹2,568 Cr (+7% YoY) and PAT of ₹195 Cr (+16% YoY). Q4 saw strong sequential recovery with 20% revenue growth, driven by Sayakha facility scale-up.

Aarti Drugs Earnings Call: Key Takeaways

Aarti Drugs reported FY26 revenue of ₹2,568 Cr (+7% YoY) and PAT of ₹195 Cr (+16% YoY), driven by the Sayakha facility scale-up and improved export traction despite pricing pressures.

Aarti Drugs Q4 FY26 Results: Net Profit ₹55.3 Cr, Down 11.9% YoY

Aarti Drugs Ltd reported revenue from operations of ₹720.3 Cr (+6.4% YoY) and net profit of ₹55.3 Cr (-11.9% YoY) for Q4 FY26.

Key figure

Net profit ₹55.3 Cr · -11.9% YoY